New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress
- 1 August 1998
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 352, SI34-SI38
- https://doi.org/10.1016/s0140-6736(98)90017-4
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Pulmonary and Systemic Responses to Exogenous Endothelin-1 in Patients with Left Ventricular DysfunctionJournal of Cardiovascular Pharmacology, 1998
- Extracellular Matrix Remodeling in Heart FailureCirculation, 1997
- Chronic Endothelin Receptor Blockade Attenuates Progressive Ventricular Dilation and Improves Cardiac Function in Rats With Myocardial InfarctionCirculation, 1997
- Molecular and Cellular Mechanisms of Myocardial FailureThe American Journal of Cardiology, 1997
- Role of Endogenous Endothelin in Chronic Heart FailureCirculation, 1997
- Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1Circulation, 1996
- Endogenous Endothelin-1 Participates in the Maintenance of Cardiac Function in Rats With Congestive Heart FailureCirculation, 1996
- Role of endothelin in the exercise intolerance of chronic heart failureThe American Journal of Cardiology, 1995
- Endothelin in human congestive heart failure.Circulation, 1994
- Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.Circulation, 1992